TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.350
-0.100 (-6.90%)
Mar 28, 2025, 4:00 PM EDT - Market closed
TScan Therapeutics Revenue
In the year 2024, TScan Therapeutics had annual revenue of $2.82M, down -86.62%. TScan Therapeutics had revenue of $665.00K in the quarter ending December 31, 2024, a decrease of -90.78%.
Revenue (ttm)
$2.82M
Revenue Growth
-86.62%
P/S Ratio
27.13
Revenue / Employee
$14,441
Employees
195
Market Cap
76.40M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TCRX News
- 3 days ago - TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access - GlobeNewsWire
- 23 days ago - TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025 - Seeking Alpha
- 25 days ago - TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 5 weeks ago - TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 6 weeks ago - TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting - Seeking Alpha
- 3 months ago - TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium - GlobeNewsWire
- 3 months ago - TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank - GlobeNewsWire